Study to Assess the Pharmacokinetics and Pharmacodynamics of GSK461364 in Subjects With Non-Hodgkins Lymphoma
Status:
Completed
Trial end date:
2009-09-29
Target enrollment:
Participant gender:
Summary
This is a first time in human study that is being done to determine the maximum tolerated
dose and initial pharmacokinetic parameters of GSK461364, given by IV, in adult subjects with
solid tumors and Non-Hodgkins lymphoma.